This article first appeared on GuruFocus .
Release Date: May 12, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
TriSalus Life Sciences Inc ( NASDAQ:TLSI ) has significantly expanded its commercial organization, positioning itself for multi-year growth.
-
The company published a landmark real-world evidence study demonstrating the clinical and economic benefits of its PEDD technology, including fewer complications and hospitalizations.
-
Gross margins improved to 86% from 84% in the prior-year period, driven by lower average unit costs and continuous manufacturing improvements.
-
The company is actively generating new clinical evidence with 10 active studies across 24 clinical sites, enhancing its data-driven approach.
-
TriSalus Life Sciences Inc ( NASDAQ:TLSI ) has a strong cash position of $56.6 million, fully funding its strategic growth plan.
Negative Points
-
Revenue for the first quarter decreased to $8.9 million from $9.2 million in the prior-year period due to disruptions from the commercial expansion.
-
The company revised its full-year 2026 revenue guidance to $54 million to $57 million, down from previous expectations, due to lower Q1 revenues and delayed FDA clearance for TriNav Advance.
-
Net operating loss increased to $8.4 million from $7.3 million in the prior-year period, reflecting lower revenue and increased sales and marketing investments.
-
The FDA review of TriNav Advance is running approximately five months past the expected timeline, impacting revenue expectations.
-
The expansion of the sales force caused short-term disruptions, affecting 40% of sales territories and requiring time for new representatives to ramp up.
Q & A Highlights
Q: Can you quantify the disruption caused by the 40% of the sales force that was affected, and how confident are you in the business's recovery trajectory to achieve the guidance range for the year? A: (Mary Della, CEO) 60% of our sales territories were not disrupted and performed as expected, indicating no fundamental change in demand or growth. The disruption in the remaining 40% was due to changes in rep-to-manager and rep-to-physician dynamics, driven by our growth. We are confident in our recovery as the right talent and territory footprint are now in place, and we expect continuous ramp-up throughout the year.
Q: Have you achieved the doubling of the sales organization, and is there more hiring needed to complete this expansion? A: (Mary Della, CEO) We have slightly expanded beyond the initial doubling of the organization due to the unprecedented level of talent attracted. This expansion positions us well to scale the company and capture the $2.5 billion market opportunity across liver and new applications.
Q: What was the composition and size of the commercial organization before and after the expansion? A: (Mary Della, CEO) We expanded the number of territories more than double and adjusted the rep-to-manager ratio. We also added an executive level of management to engage with hospital systems and payers, positioning us to pursue 400 accounts in liver and new applications.
Q: How should we think about revenue cadence for the year, particularly for Q2? A: (David Patience, CFO) We expect a marginal sequential gain in Q2 as reps come out of training, with meaningful progress in Q3 and Q4 as productivity ramps up. The second half ramp is structurally built, and we are excited to see the contributions from the expanded team.
Q: Where do you see the new PEDD data having the most direct impact, and how will it resonate with physicians and institutions? A: (Mary Della, CEO) The real-world data validates our prospective clinical data and highlights both clinical and economic benefits. It strengthens our case for PEDD as a standard of care and inclusion in NCCN guidelines. The data's impact on lymphopenia resonates strongly with oncologists, potentially influencing both interventional radiology and oncology communities.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
